期刊文献+

α-干扰素治疗丙肝的临床效果观察

Observation on the clinical effects of α-interferon in the treatment of patients with hepatitis C
下载PDF
导出
摘要 目的:探究α-干扰素治疗丙肝的临床效果。方法:收治丙肝患者78例,按照年龄阶段的不同进行分组,给予α-干扰素进行治疗,对比、分析临床疗效的异同。结果:对比4个不同年龄的总有效率,24~34岁总有效率94.1%,35~44岁84.6%,45~55岁30.7%,55岁以上22.7%,年龄越大,应用α-干扰素治疗丙肝患者的临床疗效越低,组间进行比较,差异有统计学意义(P<0.05)。病理分期越重,临床有效率越差。结论:患者的年龄大小、病理分期的轻重都会影响α-干扰素治疗丙肝的临床效果,及时、尽早地在明确丙肝诊断后积极应用治疗α-干扰素,对临床有效率及预后具有重要意义。 Objective:To investigate the clinical effects of α-interferon in the treatment of patients with hepatitis C.Methods:78 patients with hepatitis C were selected.All patients were grouped according to different age.They were all treated byα-interferon.We compared and analyzed the similarities and differences of clinical efficacy.Results:We compared the total effective rate of 4 different ages;the total effective rate of 24~34 years old was 94.1%;35~44 years old was 84.6%;45~55 years old was 30.7%;over 55 years old was 22.7% ;the elder the age,the lower the curative effect of α-interferon in the treatment of patients with hepatitis C,comparison between groups,and the differences were statistically significant(P<0.05).The more severer of pathological stage,the worse of clinical efficiency.Conclusion:The severity of age and pathological staging of the patients will affect the clinical effect of interferon therapy for hepatitis C.α-interferon should be actively applied after clearly and timely diagnosis of hepatitis C as soon as possible,which has important significance on the prognosis and clinical efficiency.
作者 秦峰 Qin Feng(The People's Hospital of Shizhu County,Chongqing City 409100)
出处 《中国社区医师》 2016年第32期33-34,共2页 Chinese Community Doctors
关键词 Α-干扰素 丙肝 临床效果 α-interferon Hepatitis C Clinical effect
  • 相关文献

参考文献5

二级参考文献35

  • 1吕惠军.α-干扰素治疗丙肝的临床效果观察与评估[J].医学理论与实践,2005,18(6):674-675. 被引量:3
  • 2Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev, 2001, 14: 778-809.
  • 3Sen GC. Viruses and interferons. Annu Rev Microbiol, 2001, 55: 255-281.
  • 4Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med, 2006, 355: 2444-2451.
  • 5Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet, 2009, 41: 1100-1104.
  • 6Thomas DL, Thio CL, Martin ME et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 2009, 461: 798-801.
  • 7McHutchison JG, Lawitz E J, Shiffman ML, et al. Peginterferon alfa- 2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med, 2009, 361: 580-593.
  • 8Zhao SH, Chu YL, Cheng DX, et al. Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C. Int J Clin Pract, 2009, 63: 1334- 1339.
  • 9Hartwell D, Shepherd J. Pegylated and non-pegylated interferonalfa and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and meta-analysis. Int J Technol Assess Health Care, 2009, 25: 56-62.
  • 10Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet, 2010, 376: 705-716.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部